Skip to main content
. 2018 Jan 11;13:275–285. doi: 10.2147/COPD.S149633

Figure 4.

Figure 4

Yearly direct costs (euros [€]/year) stratified by frequent and non-frequent exacerbator phenotype (sum of drug costs and primary and secondary care costs).

Note: Frequent exacerbator (≥2 exacerbations per year) and non-frequent exacerbator (<2 exacerbations per year).